Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer

Completed · Phase 2

Conditions studied: Endometrial Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating women who have recurrent, stage III, or stage IV endometrial cancer.

Key facts

Study ID

NCT00005861

Run by

Gynecologic Oncology Group

Starts

2000-05-01

Last updated by the study team

2013-06-10

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Chao Family Comprehensive Cancer Center — Orange, California, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Holden Comprehensive Cancer Center — Iowa City, Iowa, United States
• New England Medical Center Hospital — Boston, Massachusetts, United States
• University of Mississippi Medical Center — Jackson, Mississippi, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
• Arthur G. James Cancer Hospital - Ohio State University — Columbus, Ohio, United States
• Brookview Research, Inc. — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.